Inmune Bio (0Y2) Stock Statistics & Valuation Metrics
Total Valuation
Inmune Bio has a market cap or net worth of EUR 36.03M. The enterprise value is EUR 26.55M.
- Market Cap
- EUR 36.03M
- Enterprise Value
- EUR 26.55M
Share Statistics
Inmune Bio has 27,753,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 27,753,790
- Owned by Insiders
- 10.81%
- Owned by Institutions
- 7.00%
Financial Efficiency
Inmune Bio’s return on equity (ROE) is -1.95 and return on invested capital (ROIC) is -125.70%.
- Return on Equity (ROE)
- -1.95
- Return on Assets (ROA)
- -1.42
- Return on Invested Capital (ROIC)
- -125.70%
- Return on Capital Employed (ROCE)
- -1.29
- Revenue Per Employee
- 2,380.952
- Profits Per Employee
- -2.19M
- Employee Count
- 21
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Inmune Bio is -2.10. Inmune Bio’s PEG ratio is -0.02.
- PE Ratio
- -2.10
- PS Ratio
- 0.00
- PB Ratio
- 1.90
- Price to FCF
- -2.47
- Price to Operating Cash Flow
- -2.59
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Inmune Bio had revenue of 50.00K and earned -45.93M in profits. Earnings per share was -1.86.
- Revenue
- 50.00K
- Gross Profit
- 50.00K
- Operating Income
- -30.87M
- Pretax Income
- -45.93M
- Net Income
- -45.93M
- EBITDA
- -45.85M
- Earnings Per Share (EPS)
- -1.86
Cash Flow
In the last 12 months, operating cash flow was -14.97M and capital expenditures -1.33M, giving a free cash flow of -16.30M billion.
- Operating Cash Flow
- -14.97M
- Free Cash Flow
- -16.30M
- Free Cash Flow per Share
- -0.61
Dividends & Yields
Inmune Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -40.51%
- Earnings Yield
- -47.54%
Stock Price Statistics
- Beta
- 1.28
- 52-Week Price Change
- -10.32%
- 50-Day Moving Average
- 1.39
- 200-Day Moving Average
- 1.39
- Relative Strength Index (RSI)
- 39.52
- Average Volume (3m)
- ―
Important Dates
Inmune Bio upcoming earnings date is Nov 05, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Inmune Bio as a current ratio of 3.55, with Debt / Equity ratio of 4.40%
- Current Ratio
- 3.55
- Quick Ratio
- 3.55
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.52
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Inmune Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Inmune Bio EV to EBITDA ratio is -1.27, with an EV/FCF ratio of -1.43.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.27
- EV to Free Cash Flow
- -1.43
- EV to Operating Cash Flow
- -1.55
Balance Sheet
Inmune Bio has EUR 18.41M in cash and marketable securities with EUR 1.41M in debt, giving a net cash position of EUR 17.01M billion.
- Cash & Marketable Securities
- EUR 18.41M
- Total Debt
- EUR 1.41M
- Net Cash
- EUR 17.01M
- Net Cash Per Share
- EUR 0.61
- Tangible Book Value Per Share
- EUR 0.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Inmune Bio is EUR 7.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 7.17
- Price Target Upside
- 416.13% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 73.88%
Scores
- Smart Score
- 6
- AI Score
- ―
